Every time an inventor shows me a new point‑of‑care in‑vitro diagnostic (IVD) idea in the lab, I love the energy. The spark in someone’s eye when they believe they’ve built the next breakthrough test? It’s infectious.

But nearly immediately — sometimes before we’ve even finished introductions — the first question comes:

“So… how much is this going to cost, and how long until it’s ready?”

For me, that’s the question with the lump in the stomach. Not because it’s unanswerable — but because no one pioneers diagnostics because they want to spend a fortune on paperwork, trials and regulators. Yet that’s almost always what it actually takes.

In vitro diagnostics promise faster decisions, earlier detection and more personalised treatment.

But behind every successful IVD is a long, expensive and often underestimated journey.

Most programmes do not fail because the science is wrong.

They fail because the path from concept to clinical reality is misunderstood.

At Maddison, we see this repeatedly. The gap is not technical capability. It is planning, design translation and commercial realism.

Here is what that journey actually looks like.

1. Early R&D is only the beginning

The first mistake many teams make is underestimating the true cost of early development.

Industry data from PMarketResearch indicates that initial R&D and prototyping for molecular diagnostics typically falls between $2 million and $5 million, with more novel or technically ambitious platforms exceeding $10 million before they are even ready for clinical validation.

At this stage, the focus is often on proving the science.

But the real risk sits elsewhere.

• Can the technology be translated into a usable product?
• Can it be manufactured consistently?
• Can it perform reliably outside controlled lab conditions?

Too often, these questions are left too late.

This is where design needs to come in early, not as styling, but as a way of de-risking usability, workflow integration and manufacturability from day one.

2. Clinical validation is where cost meets reality

Once a concept works in controlled conditions, it must prove itself in the real world.

According to Compilzen, clinical performance studies for IVDs typically cost between $500,000 and $3 million, depending on the size of the study and the number of sites involved.

These studies are not just a regulatory hurdle.

They are the first true test of whether the product works in practice.

Common failure points include:

• Poor usability leading to inconsistent results
• Workflow mismatch within clinical settings
• Variability in sample handling or operator use

In other words, design issues.

If these are not resolved before clinical studies begin, costs escalate quickly through redesigns, repeated studies and delayed timelines.

3. Regulation is not a step, it is a system

Regulatory approval is often treated as a milestone at the end of development. In reality, it is a system that must be built alongside the product.

MedTech Europe reports that implementing a quality management system such as ISO 13485 typically costs between $20,000 and $100,000+ for initial certification, with ongoing annual costs. On top of this, regulatory submissions in the EU and US can reach hundreds of thousands of dollars, particularly for higher risk devices.

But the real cost is not the fees.

It is the discipline required:

• Design controls
• Risk management
• Human factors engineering
• Structured documentation throughout development

If these are not embedded early, teams are forced into expensive rework to meet regulatory expectations.

4. The real number: total cost to market

When all elements are combined, the true cost becomes clear.

Compilzen suggests that simpler point of care IVDs typically require total investment in the range of $5 million to $25 million, while more complex laboratory systems can reach $25 million to $100 million.

This aligns with broader industry analysis from FinancialModel.net, which places the cost of bringing a typical IVD to market somewhere between $20 million and $75 million, depending on complexity and risk.

Crucially, these figures assume things go broadly to plan.

Delays, redesigns and failed studies can significantly increase spend without adding value.

5. Time is the hidden cost

Even when budgets are understood, timelines are often underestimated.

According to Zimmer & Peacock, the journey from concept to commercial IVD typically spans seven years or more, covering iterative R&D, clinical testing and regulatory approval.

During that time:

• Technology evolves
• Competitors move
• Regulatory frameworks shift
• Investor pressure increases

The longer the timeline, the greater the commercial risk.

Speed is not about cutting corners.

It is about making the right decisions early.

Where value is really created

The companies that succeed are not the ones with the best science alone.

They are the ones that:

• Translate technology into usable products early
• Design for clinical workflow, not just performance
• Build regulatory thinking into development from day one
• Reduce iteration cycles before they become expensive

In short, they close the gap between possibility and reality.

The Maddison perspective

At Maddison, we work at that intersection.

Not to make devices look better, but to make them work in the real world.

Because in IVD development, value is not created in the lab alone.

It is created in the decisions made before the first clinical study begins.

Final thought

If you take one thing from this, it should be this:

The cost of an IVD is not defined by how much you spend.

It is defined by when you make the right decisions.

Get those decisions right early, and you control cost, time and risk.

Get them wrong, and the numbers above are just the starting point.